# OnCo record ksq-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/ksq-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "ksq-therapeutics" ;
  schema:name "KSQ Therapeutics"@en ;
  schema:alternateName "KSQ Therapeutics, Inc."@en, "KSQ"@en ;
  schema:description "KSQ Therapeutics makes treatments from a patient's own tumour-fighting immune cells, gene-edited to work harder and last longer, for solid tumours such as melanoma, head and neck cancer and lung cancer. Two are in early trials at MD Anderson."@en ;
  schema:url <https://onco.cc/companies/ksq-therapeutics/>, <https://ksqtx.com/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://ksqtx.com/>, <https://ksqtx.com/pipeline/>, <https://ksqtx.com/about/>, <https://ksqtx.com/partners/>, <https://ksqtx.com/press-releases/ksq-therapeutics-emerges-with-76-million-in-financing-to-pioneer-high-confidence-drug-development/>, <https://clinicaltrials.gov/study/NCT06237881> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/nsclc/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/>, <https://onco.cc/fronts/immunotherapy/>, <https://onco.cc/fronts/drug-discovery/> ;
  onco:technologies <https://onco.cc/technologies/til-therapy/>, <https://onco.cc/technologies/crispr-screens/> ;
  onco:targets <https://onco.cc/targets/socs1/> ;
  onco:drugs <https://onco.cc/drugs/ksq-001ex/>, <https://onco.cc/drugs/ksq-004ex/>, <https://onco.cc/drugs/ksq-4279/> .